Physician profile
Alejandro E Lopez
NPI 1699021337
$10,200.48
in general payments reported to CMS, 2019-2025
43 companies · $2,681 in 2025
The $2,681 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $887 · 2021: $1,109 · 2022: $1,199 · 2023: $1,507 · 2024: $1,800 · 2025: $2,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,114 · Travel and Lodging: $816 · Education: $32.27 · Debt Forgiveness: $24.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,114.35 |
| Travel and Lodging | $816.38 |
| Education | $32.27 |
| Debt Forgiveness | $24.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,308.89 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boston Scientific Corporation | $1,284.98 | 2022-2025 | Watchman, Watchman Access System |
| Abbott Laboratories | $998.67 | 2019-2025 | Jot Dx, Confirm Rx, Aveir |
| Boehringer Ingelheim Pharmaceuticals, INC. | $995.18 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $787.28 | 2022-2025 | |
| Novo Nordisk INC | $744.98 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $563.70 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $440.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $421.05 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $378.99 | 2019-2021 | |
| Medtronic, INC. | $301.81 | 2021-2025 | Synchromedii |
| Janssen Pharmaceuticals, INC | $283.64 | 2019-2020 | |
| Redhill Biopharma INC. | $155.79 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Pfizer INC. | $154.03 | 2023-2025 | |
| Amarin Pharma, INC. | $125.02 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.